{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:54:36Z","timestamp":1789512876726,"version":"build-2803163510"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.juro.2013.05.022","type":"journal-article","created":{"date-parts":[[2013,5,18]],"date-time":"2013-05-18T07:31:25Z","timestamp":1368862285000},"page":"2194-2199","source":"Crossref","is-referenced-by-count":38,"title":["Outcomes of Intralesional Interferon-\u03b12B for the Treatment of Peyronie Disease"],"prefix":"10.1097","volume":"190","author":[{"given":"Landon W.","family":"Trost","sequence":"first","affiliation":[{"name":"Tulane University, New Orleans, Louisiana, and Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhan","family":"Ates","sequence":"additional","affiliation":[{"name":"Tulane University, New Orleans, Louisiana, and Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Powers","sequence":"additional","affiliation":[{"name":"Tulane University, New Orleans, Louisiana, and Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Sikka","sequence":"additional","affiliation":[{"name":"Tulane University, New Orleans, Louisiana, and Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne J.G.","family":"Hellstrom","sequence":"additional","affiliation":[{"name":"Tulane University, New Orleans, Louisiana, and Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2013.05.022_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1464-4096.2001.02436.x","article-title":"The prevalence of Peyronie\u2019s disease: results of a large survey","volume":"88","author":"Schwarzer","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2013.05.022_bib2","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1097\/01.ju.0000127744.18878.f1","article-title":"Subjective and objective analysis of the prevalence of Peyronie\u2019s disease in a population of men presenting for prostate cancer screening","volume":"171","author":"Mulhall","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.05.022_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ijir.3901518","article-title":"The prevalence of Peyronie\u2019s disease in diabetic patients with erectile dysfunction","volume":"19","author":"Arafa","year":"2007","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.juro.2013.05.022_bib4","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4321\/S0004-06142007000300021","article-title":"The natural history of Peyronie\u2019s disease","volume":"60","author":"Grasso","year":"2007","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.juro.2013.05.022_bib5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","article-title":"EAU guidelines on penile curvature","volume":"62","author":"Hatzimouratidis","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.05.022_bib6","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.eururo.2006.10.042","article-title":"Systematic evidence-based analysis of plaque injection therapy for Peyronie\u2019s disease","volume":"51","author":"Russell","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.05.022_bib7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","article-title":"Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie\u2019s disease","volume":"176","author":"Hellstrom","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.05.022_bib8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety, and tolerability of collagenase clostridium histolyticum in the treatment of Peyronie\u2019s disease from 2 large double-blind, randomized, placebo-controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.05.022_bib9","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.05.022_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-5347(17)35998-0","article-title":"Collagenase versus placebo in the treatment of Peyronie\u2019s disease: a double-blind study","volume":"149","author":"Gelbard","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.05.022_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0022-5347(17)35996-7","article-title":"Standardization of penile blood flow parameters in normal men using intracavernous prostaglandin E1 and visual sexual stimulation","volume":"149","author":"Lee","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.05.022_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1743-6109.2005.00110.x","article-title":"The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie\u2019s disease","volume":"2","author":"Kendirci","year":"2005","journal-title":"J Sex Med"},{"key":"10.1016\/j.juro.2013.05.022_bib13","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.juro.2013.05.022_bib14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0022-5347(05)64691-5","article-title":"Experience with intraplaque injection of verapamil for Peyronie\u2019s disease","volume":"168","author":"Levine","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.05.022_bib15","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/j.1464-410X.2010.10029.x","article-title":"Defining predictors of response to intralesional verapamil injection therapy for Peyronie\u2019s disease","volume":"108","author":"Moskovic","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2013.05.022_bib16","first-page":"165","article-title":"Betamethasone versus placebo in Peyronie\u2019s disease","volume":"70","author":"Cipollone","year":"1998","journal-title":"Arch Ital Urol Androl"},{"key":"10.1016\/j.juro.2013.05.022_bib17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","article-title":"Effect of intralesional verapamil for treatment of Peyronie\u2019s disease: a randomized single-blind, placebo-controlled study","volume":"41","author":"Shirazi","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.juro.2013.05.022_bib18","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01850.x","article-title":"The management of Peyronie\u2019s disease: evidence-based 2010 guidelines","volume":"7","author":"Ralph","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.juro.2013.05.022_bib19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","article-title":"Use of intralesional verapamil to dissolve Peyronie\u2019s disease plaque: a long-term single-blind study","volume":"51","author":"Rehman","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.juro.2013.05.022_bib20","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1111\/j.1743-6109.2010.01924.x","article-title":"Nicardipine vs. saline injection as treatment for Peyronie\u2019s disease: a prospective, randomized, single-blind trial","volume":"7","author":"Soh","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.juro.2013.05.022_bib21","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1046\/j.1464-410x.2001.02139.x","article-title":"Treatment of Peyronie\u2019s disease with local interferon-alpha 2b","volume":"87","author":"Brake","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2013.05.022_bib22","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/j.1939-4640.1999.tb02539.x","article-title":"A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie\u2019s disease","volume":"20","author":"Ahuja","year":"1999","journal-title":"J Androl"},{"key":"10.1016\/j.juro.2013.05.022_bib23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000475057","article-title":"Treatment of Peyronie\u2019s disease with local interferon-alpha 2b","volume":"28","author":"Wegner","year":"1995","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.05.022_bib24","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000480857","article-title":"Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie\u2019s disease","volume":"32","author":"Wegner","year":"1997","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.05.022_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1464-410X.1997.02849.x","article-title":"Intralesional interferon in the treatment of Peyronie\u2019s disease: a pilot study","volume":"79","author":"Judge","year":"1997","journal-title":"BJU"},{"key":"10.1016\/j.juro.2013.05.022_bib26","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1743-6109.2011.02519.x","article-title":"Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie\u2019s disease","volume":"9","author":"Abern","year":"2012","journal-title":"J Sex Med"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534713043589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534713043589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2013.05.022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T17:57:14Z","timestamp":1715363834000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2013.05.022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1016\/j.juro.2013.05.022"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2013.05.022","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718011922.793523266","asserted-by":"object"}]},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}